Implementation of contemporary chemotherapy for patients with metastatic pancreatic ductal adenocarcinoma: a population-based analysis.

Conclusion: Nationwide variation in the use of chemotherapy decreased after the implementation of FOLFIRINOX and gemcitabine with nab-paclitaxel. Still a considerable proportion of patients receives gemcitabine monotherapy. Overall survival did improve, but not clinically relevant. These results emphasize the need for a structured implementation of new chemotherapeutic regimens.
PMID: 32056483 [PubMed - as supplied by publisher]

Source: Acta Oncologica - February 13, 2020 Category: Cancer & Oncology Authors: Latenstein AEJ, Mackay TM, Creemers GJ, van Eijck CHJ, de Groot JWB, Haj Mohammad N, Homs MYV, van Laarhoven HWM, Molenaar IQ, Ten Tije BJ, de Vos-Geelen J, Besselink MG, van der Geest LGM, Wilmink JW, Dutch Pancreatic Cancer Group Tags: Acta Oncol Source Type: research